Nuvation Bio NUVB
NYSE NUVB
$5.64 +0.02 (+0.36%)
As of: Sep 30, 2026 · 10:25 AM EDT

Nuvation Bio (NUVB) Convertible Debt (2026)

Updated

Nuvation Bio (NUVB) posted Convertible Debt of $242.62 million for Q2 2026.

Analysis

Nuvation Bio (NUVB) Convertible Debt (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Nuvation Bio 1.94 Bn 1.94 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 242.62 Mn
API Access

Nuvation Bio Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=NUVB&period=max&api_key=YOUR_API_KEY